EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An investigation of plasma cell-free RNA for the detection of colorectal cancer: From transcriptome marker selection to targeted validation

Emmalee J Northrop-Albrecht iD, Chung Wah Wu, Calise K Berger, William R Taylor, Patrick H Foote, Karen A Doering iD, Anna M Gonser, Aditya Bhagwate, Zhifu Sun, Douglas W Mahoney, Kelli N Burger, Lisa A Boardman und 1 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0308711 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Emmalee J Northrop-Albrecht und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States of America. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Biomarkers, Tumor, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institute of Health, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Regular screening for colorectal cancer (CRC) is critical for early detection and long-term survival. Despite the current screening options available and advancements in therapies there will be around 53,000 CRC related deaths this year. There is great interest in non-invasive alternatives such as plasma cell-free RNA (cfRNA) for diagnostic, prognostic, and predictive applications. In the current study, our aim was to identify and validate potential cfRNA candidates to improve early CRC diagnosis. In phase 1 (n = 49; 25 controls, 24 cancers), discovery total RNA sequencing was performed. Select exons underwent validation in phase 2 (n = 73; 35 controls, 29 cancers, 9 adenomas) using targeted capture sequencing (n = 10,371 probes). In phase 3 (n = 57; 30 controls, 27 cancers), RT-qPCR was performed on previously identified candidates (n = 99). There were 895 exons that were differentially expressed (325 upregulated, 570 downregulated) among cancers versus controls. In phases 2 and 3, fewer markers were validated than expected in independent sets of patients, most of which were from previously published literature (FGA, FGB, GPR107, CDH3, and RP23AP7). In summary, we optimized laboratory processes and data analysis strategies which can serve as methodological framework for future plasma RNA studies beyond just the scope of CRC detection. Additionally, further exploration is needed in order to determine if the few cfRNA candidates identified in this study have clinical utility for early CRC detection. Over time, advancements in technologies, data analysis, and RNA preservation methods at time of collection may improve the biological and technical reproducibility of cfRNA biomarkers and enhance the feasibility of RNA-based liquid biopsies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsBiomarkers, TumorCell-Free Nucleic AcidsHumansMaleFemaleMiddle AgedAgedTranscriptomeEarly Detection of CancerGene Expression Regulation, NeoplasticSequence Analysis, RNACase-Control Studies

Substanzen

Biomarkers, TumorCell-Free Nucleic Acids

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States of America.
  • Division of Computational Biology, Mayo Clinic, Rochester, Minnesota, United States of America.
  • Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, United States of America.

ORCID-Profile: Emmalee J Northrop-Albrecht, Karen A Doering

Förderung

  • NCI NIH HHS
  • National Institute of Health
  • National Cancer Institute

Zitieren

APA

Northrop-Albrecht, E. J., Wu, C. W., Berger, C. K., Taylor, W. R., Foote, P. H., Doering, K. A., Gonser, A. M., Bhagwate, A., Sun, Z., Mahoney, D. W., Burger, K. N., Boardman, L. A., & Kisiel, J. B. (2024). An investigation of plasma cell-free RNA for the detection of colorectal cancer: From transcriptome marker selection to targeted validation. PLOS ONE. https://doi.org/10.1371/journal.pone.0308711

Vancouver

Northrop-Albrecht EJ, Wu CW, Berger CK, Taylor WR, Foote PH, Doering KA, et al. An investigation of plasma cell-free RNA for the detection of colorectal cancer: From transcriptome marker selection to targeted validation. PLOS ONE. 2024. doi:10.1371/journal.pone.0308711

BibTeX
@article{NorthropAlbrecht2024,
  author = {Northrop-Albrecht, Emmalee J and Wu, Chung Wah and Berger, Calise K and Taylor, William R and Foote, Patrick H and Doering, Karen A and Gonser, Anna M and Bhagwate, Aditya and Sun, Zhifu and Mahoney, Douglas W and Burger, Kelli N and Boardman, Lisa A and Kisiel, John B},
  title = {An investigation of plasma cell-free RNA for the detection of colorectal cancer: From transcriptome marker selection to targeted validation},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0308711}
}
Kostenlos starten →